New evidence with high certainty emerged that glucagon-like peptide-1 receptor agonist (GLP-1RA) use was also associated with a lower risk of COVID-19-related death (SRR 0.83 [95% CI 0.71, 0.97], n=9 studies [ESM Fig. 31]). Here, GLP1R is linked to COVID-19.